KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Tax Provisions: 2009-2025

Historic Tax Provisions for Teva Pharmaceutical Industries (TEVA) over the last 14 years, with Sep 2025 value amounting to $214.0 million.

  • Teva Pharmaceutical Industries' Tax Provisions rose 210.14% to $214.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.0 million, marking a year-over-year decrease of 65.41%. This contributed to the annual value of $676.0 million for FY2024, which is 9757.14% up from last year.
  • Teva Pharmaceutical Industries' Tax Provisions amounted to $214.0 million in Q3 2025, which was up 374.36% from -$78.0 million recorded in Q2 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Tax Provisions peaked at $630.0 million during Q2 2024, and registered a low of -$900.0 million during Q2 2022.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Tax Provisions value was $28.0 million (recorded in 2024), while the average stood at $79.9 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Tax Provisions tumbled by 1,050.00% in 2023 and then skyrocketed by 4,037.50% in 2024.
  • Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Tax Provisions stood at -$24.0 million in 2021, then surged by 720.83% to $149.0 million in 2022, then plummeted by 72.48% to $41.0 million in 2023, then plummeted by 31.71% to $28.0 million in 2024, then skyrocketed by 210.14% to $214.0 million in 2025.
  • Its last three reported values are $214.0 million in Q3 2025, -$78.0 million for Q2 2025, and $74.0 million during Q1 2025.